# EDGAR Filing Document

**Accession Number:** 0001648257
**File Stem:** 0001648257-25-000087
**Filing Date:** 2025-12
**Character Count:** 14012
**Document Hash:** a7b33d6d1b7cd6925eec921bf45b543f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001648257-25-000087.hdr.sgml**: 20251229

**ACCESSION NUMBER**: 0001648257-25-000087

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 5

**CONFORMED PERIOD OF REPORT**: 20251229

**FILED AS OF DATE**: 20251229

**DATE AS OF CHANGE**: 20251229

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HUTCHMED (China) Ltd
- **CENTRAL INDEX KEY:** 0001648257
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37710
- **FILM NUMBER:** 251602426

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 48TH FLOOR, CHEUNG KONG CENTER
- **STREET 2:** 2 QUEEN'S ROAD CENTRAL
- **CITY:** HONG KONG
- **PROVINCE COUNTRY:** K3
- **BUSINESS PHONE:** 852-2121-3888

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 48TH FLOOR, CHEUNG KONG CENTER
- **STREET 2:** 2 QUEEN'S ROAD CENTRAL
- **CITY:** HONG KONG
- **PROVINCE COUNTRY:** K3

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Hutchison China MediTech Ltd
- **DATE OF NAME CHANGE:** 20150716

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM 6-K**

------

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE**

**SECURITIES EXCHANGE ACT OF 1934**

**For the Month of December 2025**

**Commission File Number: 001-37710**

------

**HUTCHMED (CHINA) LIMITED**

(Translation of registrant's name into English)

------

**48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong**

(Address of principal executive offices)

------

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F ◻

------

**HUTCHMED (CHINA) LIMITED**

**Form 6-K**

<u>EXHIBIT INDEX</u>

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| Exhibit 99.1 | **Announcement relating to blocklisting six monthly return**<br>|
| Exhibit 99.2 | Press release relating to NDA Acceptance in China with priority review status for fanregratinib in second-line intrahepatic cholangiocarcinoma |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| HUTCHMED (CHINA) LIMITED | HUTCHMED (CHINA) LIMITED |
| By: | /s/ Johnny Cheng |
| Name: | Johnny Cheng |
| Title: | Chief Financial Officer |

---

Date: December 29, 2025

------

## Exhibit 99.1

**Exhibit 99.1**

![Graphic](hcm-20251229xex99d1001.gif)

**Blocklisting Six Monthly Return**

**Hong Kong, Shanghai, & Florham Park, NJ — Monday, December 29, 2025:** HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return:

---

| | | |
|:---|:---|:---|
| 1. | Name of applicant:<br>| HUTCHMED (China) Limited  |
| 2. | Name of scheme: | Share Option Scheme conditionally adopted by HUTCHMED in 2015 ("2015 HUTCHMED Share Option Scheme") |
|  | Name of scheme: | Share Option Scheme conditionally adopted by HUTCHMED in 2015 ("2015 HUTCHMED Share Option Scheme") |
| 3. | Period of return:<br>| From June 29, 2025 to December 28, 2025 |
| 4. | Balance under scheme from previous return: | 2015 HUTCHMED Share Option Scheme: 45,992,018 ordinary shares of US$0.1 each |
| 4. | Balance under scheme from previous return: | 2015 HUTCHMED Share Option Scheme: 45,992,018 ordinary shares of US$0.1 each |
| 5. | The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:  | 2015 HUTCHMED Share Option Scheme: Nil |
|  | The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:  | 2015 HUTCHMED Share Option Scheme: Nil |
| 6. | Number of securities issued/allotted under scheme during period: | 2015 HUTCHMED Share Option Scheme: 216,150 |
|  | Number of securities issued/allotted under scheme during period: | 2015 HUTCHMED Share Option Scheme: 216,150 |
| 7. | Balance under scheme not yet issued/allotted at end of the period: | 2015 HUTCHMED Share Option Scheme: 45,775,868 ordinary shares of US$0.1 each |
|  | Balance under scheme not yet issued/allotted at end of the period: | 2015 HUTCHMED Share Option Scheme: 45,775,868 ordinary shares of US$0.1 each |
| 8. | Number and class of securities originally listed and the date of admission: | 25,198,880 ordinary shares of US$0.1 each admitted on June 17, 2019 (to replace the Company's previous block admission schemes following the Company's share subdivision which took effect on May 30, 2019) |
|  | Number and class of securities originally listed and the date of admission: | 25,198,880 ordinary shares of US$0.1 each admitted on June 17, 2019 (to replace the Company's previous block admission schemes following the Company's share subdivision which took effect on May 30, 2019) |
|  | Number and class of securities originally listed and the date of admission: | 25,198,880 ordinary shares of US$0.1 each admitted on June 17, 2019 (to replace the Company's previous block admission schemes following the Company's share subdivision which took effect on May 30, 2019) |
|  | Number and class of securities originally listed and the date of admission: | 25,198,880 ordinary shares of US$0.1 each admitted on June 17, 2019 (to replace the Company's previous block admission schemes following the Company's share subdivision which took effect on May 30, 2019) |
|  | Number and class of securities originally listed and the date of admission: |  |
| 9. | Total number of securities in issue at the end of the period:<br>| 872,327,620 ordinary shares of US$0.1 each |
| Name of contact: | Name of contact: | Weiguo Su / Johnny Cheng |
| Address of contact: | Address of contact: | Level 18, The Metropolis Tower, 10 Metropolis Drive, Hung Hom, Kowloon, Hong Kong  |
| Telephone number of contact: | Telephone number of contact: | +852 2121 8200 |

---

------

**About HUTCHMED**

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

**CONTACTS**

---

| | |
|:---|:---|
| **Investor Enquiries** | +852 2121 8200 / <u>ir@hutch-med.com</u> |
| **Media Enquiries** |  |
| FTI Consulting – | +44 20 3727 1030 / <u>HUTCHMED@fticonsulting.com</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;Ben Atwell / Tim Stamper | &nbsp;&nbsp;&nbsp;&nbsp;+44 7771 913 902 (Mobile) / +44 7421 898 348 (Mobile) |
| Brunswick – Zhou Yi | +852 9783 6894 (Mobile) / <u>HUTCHMED@brunswickgroup.com</u> |
| **Panmure Liberum** | *Nominated Advisor and Joint Broker* |
| Atholl Tweedie / Emma Earl / Rupert Dearden | +44 20 7886 2500 |
| **Cavendish** | *Joint Broker* |
| Geoff Nash / Nigel Birks | +44 20 7220 0500 |
| **Deutsche Numis** | *Joint Broker* |
| Freddie Barnfield / Jeffrey Wong / Duncan Monteith | +44 20 7260 1000 |

---

------

## Exhibit 99.2

**Exhibit 99.2**

![Graphic](hcm-20251229xex99d2001.gif)

**Press Release**

**HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma**

*— NDA supported by results from a Phase II registration trial in China —*

*— Second most common form of liver cancer after hepatocellular carcinoma, with generally poorer long-term survival in comparison —*

**Hong Kong, Shanghai & Florham Park, NJ — Monday, December 29, 2025:** HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application ("NDA") for fanregratinib (HMPL-453) for the treatment of adult patients with advanced, metastatic or unresectable intrahepatic cholangiocarcinoma ("ICC") with fibroblast growth factor receptor ("FGFR") 2 fusion/rearrangement who have previously received systemic therapy has been accepted and granted priority review by the China National Medical Products Administration ("NMPA").

Fanregratinib (HMPL-453) is a novel, selective, oral inhibitor targeting FGFR 1/2/3. ICC is a highly aggressive malignancy arising from the intrahepatic biliary epithelium. It accounts for 8.2-15.0% of primary liver cancers, and consequently it is the second most common type after hepatocellular carcinoma. In recent years, the incidence of ICC has continued to rise, with a 5-year overall survival rate of approximately 9%.<sup>1</sup> Approximately 10-15% of ICC patients globally have tumors harboring FGFR2 fusions or rearrangements.<sup>2,3</sup>

This NDA is supported by data from a single-arm, multi-center, open-label, Phase II registration study in China. The study has met its primary endpoint of objective response rate (ORR). Results from the secondary endpoints including progression-free survival (PFS), disease control rate (DCR), duration of response (DoR) and overall survival (OS) also support the primary endpoint findings. Full results will be submitted for presentation at an upcoming scientific conference. Additional details may be found at clinicaltrials.gov using identifier NCT04353375.

#### About Fanregratinib
Fanregratinib (HMPL-453) is a novel, highly selective and potent inhibitor targeting FGFR 1, 2 and 3. Aberrant FGFR signaling has been found to be a driving force in tumor growth, promotion of angiogenesis and resistance to anti-tumor therapies. Abnormal FGFR gene alterations are believed to be the drivers of tumor cell proliferation in several solid tumor settings. HUTCHMED currently retain all rights to fanregratinib worldwide.

#### About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

------

#### Forward-Looking Statements
*This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED's current expectations regarding future events, including its expectations regarding the review of a NDA for fanregratinib for the treatment of ICC with the NMPA and the timing of such review, therapeutic potential of fanregratinib for the treatment of patients with ICC and the further development of fanregratinib in this and other indications. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding the timing and outcome of clinical studies and the sufficiency of clinical data to support NDA approval of fanregratinib for the treatment of patients with ICC or other indications in China or other jurisdictions, its potential to gain approvals from regulatory authorities on an expedited basis or at all, the safety profile of fanregratinib, HUTCHMED's ability to fund, implement and complete its further clinical development and commercialization plans for fanregratinib and the timing of these events. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED's filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.*

**CONTACTS**

---

| | |
|:---|:---|
| **Investor Enquiries** | +852 2121 8200 / <u>ir@hutch-med.com</u> |
| **Media Enquiries** |  |
| FTI Consulting – | +44 20 3727 1030 / <u>HUTCHMED@fticonsulting.com</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;Ben Atwell / Tim Stamper | &nbsp;&nbsp;&nbsp;&nbsp;+44 7771 913 902 (Mobile) / +44 7421 898 348 (Mobile) |
| Brunswick – Zhou Yi | +852 9783 6894 (Mobile) / <u>HUTCHMED@brunswickgroup.com</u> |
| **Panmure Liberum** | *Nominated Advisor and Joint Broker* |
| Atholl Tweedie / Emma Earl / Rupert Dearden | +44 20 7886 2500 |
| **Cavendish** | *Joint Broker* |
| Geoff Nash / Nigel Birks | +44 20 7220 0500 |
| **Deutsche Numis** | *Joint Broker* |
| Freddie Barnfield / Jeffrey Wong / Duncan Monteith | +44 20 7260 1000 |

---

_________________________________________

**REFERENCES**

1 Expert consensus on precision detection of intrahepatic cholangiocarcinoma (2024 edition). *Chin J Clin Med*. 2025;32(1):1-18.

2 Arai Y, Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. *Hepatology.* 2014;59:1427–34.

3 Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. *Nat Genet.* 2015;47:1003–10.

------